ClinicalTrials.gg

Program

Tenecteplase

Also written as “tenecteplase”, “rhTNK-tPA” and “GNR-060”.

Its studies are mostly in Myocardial Infarction · Ischemic Stroke · ST Elevation Myocardial Infarction · Stroke · Heart Arrest, led by 4 companies.

Furthest: phase 4, since Sep 9, 200516 company-led studies, 2 open or runningNext primary completion: Sep 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim81 open or runningphase 4since Sep 9, 2005Sep 7, 2005Oct 2, 2027phase 3 · NCT07361302
Hoffmann-La Roche50 open or runningphase 3since Nov 2, 2006Nov 2, 2006none ahead
CSPC Pharmaceutical Group21 open or runningphase 4since Jun 12, 2016Jun 12, 2016Sep 30, 2027phase 3 · NCT07201688
AO GENERIUM10 open or runningphase 3since Oct 26, 2022Oct 26, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 7, 2005First studies: 2 phase 3 studiesNew to Boehringer IngelheimBoehringer Ingelheim · NCT00148460, NCT00157261
  2. Sep 9, 2005Phase 4 study in Myocardial InfarctionBoehringer Ingelheim · NCT00168792 · 1,671 enrolled · United States, Austria, Belgium and more
  3. Nov 2, 2006Hoffmann-La Roche's first studies: 4 phase 3 studiesNew to Hoffmann-La RocheHoffmann-La Roche · NCT00396318, NCT00396253, NCT00396032 and 1 more
  4. Feb 15, 2008Phase 3 study in Myocardial InfarctionBoehringer Ingelheim · NCT00623623 · 1,899 enrolled · Austria, Belgium, Brazil and more
  5. Jul 2, 20142 phase 3 studies in Myocardial InfarctionBoehringer Ingelheim · NCT02182011, NCT02181985
  6. Jun 12, 2016CSPC Pharmaceutical Group's first study: phase 4 study in Acute ST Elevation Myocardial InfarctionNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT02835534 · 818 enrolled · China
  7. Dec 19, 2018Phase 3 study in THROMBOLYSISHoffmann-La Roche · NCT03785678 · 458 enrolled · United States, Canada
  8. Jun 4, 2021Phase 3 study in StrokeBoehringer Ingelheim · NCT04915729 · 1,489 enrolled · China
  9. Oct 26, 2022AO GENERIUM's first study: phase 3 study in ST Elevation Myocardial InfarctionNew to AO GENERIUMAO GENERIUM · NCT05601999 · 244 enrolled · Russia
  10. Sep 22, 2025Phase 3 study in Ischemic StrokeCSPC Pharmaceutical Group · NCT07201688 · 890 planned · China
  11. Jan 14, 2026Phase 3 study in Ischemic StrokeBoehringer Ingelheim · NCT07361302 · 1,325 planned · Argentina, Australia, Bulgaria and more

Ahead

  1. Sep 30, 2027Primary completion: phase 3 study in Ischemic StrokeCSPC Pharmaceutical Group · NCT07201688
  2. Oct 2, 2027Primary completion: phase 3 study in Ischemic StrokeBoehringer Ingelheim · NCT07361302

TargetBeta

PLAT →read by rule
“Tissue-type plasminogen activator exogenous protein”ChEMBL 37, by rule

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07361302Ischemic Stroke · Argentina, Australia, Bulgaria and more3RecruitingBoehringer IngelheimOct 2, 20271,325
NCT07201688Ischemic Stroke · China3RecruitingCSPC Pharmaceutical GroupSep 30, 2027890
NCT05601999ST Elevation Myocardial Infarction · Russia3CompletedAO GENERIUMMay 6, 2024244
NCT04915729Stroke · China3CompletedBoehringer IngelheimOct 8, 20231,489
NCT03785678THROMBOLYSIS · United States, Canada3CompletedHoffmann-La RocheFeb 28, 2023458
NCT02835534Acute ST Elevation Myocardial Infarction · China4CompletedCSPC Pharmaceutical GroupOct 2019818
NCT02182011Myocardial Infarction3CompletedBoehringer IngelheimJun 200149
NCT02181985Myocardial Infarction3CompletedBoehringer IngelheimApr 20015,989
NCT00623623Myocardial Infarction · Austria, Belgium, Brazil and more3CompletedBoehringer IngelheimSep 1, 20121,899
NCT00396318Dysfunctional Central Venous Access Catheters3CompletedHoffmann-La RocheJun 2008251
NCT00396253Dysfunctional Hemodialysis Catheters3CompletedHoffmann-La RocheOct 2008223
NCT00396032Renal Insufficiency3CompletedHoffmann-La RocheDec 2008150
NCT00395876Dysfunctional Central Venous Access Catheters3CompletedHoffmann-La RocheJun 2008100
NCT00168792Myocardial Infarction · United States, Austria, Belgium and more4TerminatedBoehringer IngelheimJul 20061,671
NCT00157261Heart Arrest · Austria, Belgium, France and more3TerminatedBoehringer IngelheimJun 20061,050
NCT00148460Myocardial Infarction · China, Hong Kong, Korea, Republic of3CompletedBoehringer Ingelheim270

How it is read

Names in the registry

  • “tenecteplase”, 6 entries
  • “Tenecteplase”, 5 entries
  • “rhTNK-tPA”, 2 entries
  • “GNR-060”, 1 entry
  • “Full dose TNK-tPA”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.